NDAORALTABLET
Approved
Oct 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MODERIL (rescinnamine) is an oral tablet small-molecule antihypertensive approved in 1956 by Pfizer. Rescinnamine is a Rauwolfia alkaloid derivative that acts as a sympathomimetic antagonist to reduce blood pressure. The drug is indicated for hypertension management in adult patients.
LOE Approaching
With LOE approaching and minimal current linked job activity, this product likely operates as a legacy franchise with a small, maintenance-focused team rather than growth-driven expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MODERIL represents a legacy asset with minimal career momentum; professionals joining this product should expect maintenance-focused responsibilities and limited advancement opportunities. This role suits candidates seeking stability in a mature product portfolio rather than growth or innovation-driven career trajectories.
Brand Manager (Legacy Products)Field Sales Representative
Worked on MODERIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.